Optimizing Treatment Approaches in Patients with HER2+ Metastatic Breast Cancer: Insights From Experts at the Dana Farber Cancer Institute

Expert panelists open their discussion on HER2+ breast cancer by reviewing a patient case of metastatic disease with no CNS involvement.

Comprehensive insight to the treatment armamentarium for HER2+ metastatic breast cancer throughout several lines of therapy.

Having outlined available treatment options for patients with HER2+ metastatic breast cancer, expert panelists share which factors help to select optimal therapy.

A brief review on how best to identify, delay, or avoid brain metastases in patients diagnosed with metastatic HER2+ breast cancer.

Switching to a patient case of brain metastases in HER2+ breast cancer, panelists highlight available therapeutic strategies in this setting.

Shared consideration on the factors that dictate selection of optimal therapy for patients with HER2+ breast cancer and brain metastases.

Expert perspectives on the respective role of radiation therapy to manage brain metastases in the setting of HER2+ breast cancer.

A panel of expert oncologists highlight the use of the tucatinib, trastuzumab and capecitabine regimen that was investigated in the HER2CLIMB trial to manage patients with HER2+ breast cancer and brain metastases.

Panelists reflect on sequencing therapy for HER2+ metastatic breast cancer following disease progression on the tucatinib, trastuzumab and capecitabine regimen.

Comprehensive review of novel combination treatment strategies being explored for patients with HER2+ breast cancer and brain metastases.

Following review of the final patient scenario, panelists consider later-line treatment options in the setting of multiply relapsed HER2+ metastatic breast cancer.

A brief review on how best to use MRI following CNS-directed radiation therapy in patients with HER2+ metastatic breast cancer.

Centering discussion on trastuzumab deruxtecan use in HER2+ metastatic breast cancer, experts elucidate adverse event management and concurrent radiation therapy.

Experts share brief insights on novel agents in development for HER2+ breast cancer and consider how they may impact the treatment landscape.

Panelists center their discussion on the challenges inherent in managing leptomeningeal metastases in patients with HER2+ breast cancer.

Closing out their review of the HER2+ metastatic breast cancer treatment landscape, expert oncologists look forward to future evolutions in the paradigm.

Based on several patient cases, expert oncologists review the evolving treatment landscape of HER2+ breast cancer with a focus on brain metastases.